Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Your Basket's Financial Footprint
Concise interpretation of the basket's market capitalisation and investor-focused takeaways.
- Large-cap dominance tends to reduce volatility, offering greater stability and closer market-like performance than small-cap baskets.
- Suitable as a core holding for diversified portfolios, not as a speculative, high-risk trade.
- Expect steady, long-term appreciation rather than explosive short-term gains; manage upside expectations accordingly.
ALNY: $62.13B
IONS: $11.42B
CRSP: $6.58B
- Other
About This Group of Stocks
Our Expert Thinking
Recent safety setbacks in viral vector gene therapies have created an opportunity for companies developing alternative approaches. This collection focuses on innovators using non-viral technologies like siRNA, antisense oligonucleotides, and CRISPR that may offer safer ways to treat genetic diseases.
What You Need to Know
This is a high-growth, high-risk thematic investment in cutting-edge biotechnology. These companies are developing next-generation genetic medicines that could potentially transform treatment for many diseases, but many are still in development stages with uncertain regulatory paths.
Why These Stocks
These companies were selected for their leadership in non-viral genetic medicine approaches that may gain favor as the market reassesses viral vector risks. They represent diverse technologies and development stages, giving exposure to multiple potential breakthrough platforms in this evolving sector.
Why You'll Want to Watch These Stocks
Industry Pivot Point
Safety concerns with traditional gene therapies are triggering a major shift in the biotech industry. These companies could be perfectly positioned to capture new investment as the market seeks safer alternatives.
Next-Gen Breakthrough Potential
These pioneers are developing cutting-edge technologies that could transform genetic medicine. Many are working on platforms that could treat previously untouchable diseases without the risks of viral vectors.
Under-the-Radar Opportunity
While media attention has focused on viral vector setbacks, smart money is quietly shifting toward these alternative approaches. These stocks may be undervalued before the broader market fully recognizes the potential shift.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Digital Trust Stocks | Cybersecurity Investment Opportunity
Fifteen global tech giants, led by Microsoft and Ericsson, have formed an alliance to establish a common framework for digital trust and security. This move signals a growing demand for specialized cybersecurity and verification technologies, creating an investment opportunity in companies that provide the essential tools for a trusted digital ecosystem.
Food Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Founder-Controlled Stocks May Gain Focus in 2025
SpaceX is reportedly considering a dual-class share structure for its IPO to ensure founder Elon Musk retains control. This move could spark investor interest in other public companies where founders or insiders hold significant voting power through similar stock structures.